OXIS International, Inc. (OTCMKTS:OXIS)
OXIS International, Inc. (OTCMKTS:OXIS) stock was up by 60.98% in Monday’s trading session as investors await an upcoming conference where the company plans to discuss its oncology and central nervous system drugs. More than 300 companies will attend the conference scheduled for September 10 to September 12 at the Lotte New York Palace Hotel.
OXIS Stock Price Chart:
Shares of OXIS International, Inc. (OTCMKTS:OXIS) are up by more than 100% since the end of July and currently trading at the higher end of $06 – $0.09 trading range. The stock’s impressive run, which began last month, faces a major test at the $0.10 a share mark, which is acting as a key resistance level. Above the $0.10 mark, the stock could rally to highs of $0.20 a share.
OXIS International, Inc. (OTCMKTS:OXIS) is an immuno-oncology company focused on the treatment of cancer and other unmet medical needs. Its candidate drug is 0XS-1550 designed to target cancer cells expressing the CD19 receptor or CD22 receptor.
Fuelling the bullish momentum on OXIS International, Inc. (OTCMKTS:OXIS) stock is the pending merger with GT BioPharma and Georgetown Translational Pharmaceutical. The merger will result in a combined company that combines Oxis promising oncology drugs as well as GT BioPharma central nervous systems drugs. The deal should close before September 30, 2017.
“The merger of GT BioPharma, Inc. (Oxis) and GTP will greatly accelerate the clinical development of exciting new treatments to meet the medical needs of those suffering from cancer and neurologic diseases,” said CEO Dr. Clarence-Smith.
OXIS International, Inc. (OTCMKTS:OXIS) in partnership with Europe Paris Oxis has confirmed the enrollment of four patients as part of a Foods and Drug Administration approved Phase 2 Clinical trial of 0XS-1550. The trial is currently being conducted by the University of Minnesota’s Masonic Cancer Center.
Researchers at the university have already completed a Phase 1 trial of the promising cancer therapy where they ascertained safety and effective dosage. Phase 2 trial results are slated for release sometime in the first quarter of 2018.
“The product performed well in Phase 1 studies of blood cancers and we look forward to providing a targeted immunotherapy product that has the capability of treating a number of different liquid tumors,” said Anthony Cataldo, Executive Chairman of GT BioPharma.
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
Don’t miss out! Stay informed on $OXIS and receive breaking news on other hot stocks by signing up for our free newsletter!
About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.